Robert Barrie is a journalist specializing in the medical and pharmaceutical industries. He writes for publications such as Medical Device Network, Pharmaceutical-Technology, and Clinical Trials Arena, covering topics ranging from new medical devices and therapies to clinical trial advancements. His work has also been featured in The Redstone Rocket.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Robert Barrie appears to focus extensively on the healthcare and pharmaceutical industry, with a particular emphasis on company announcements and press releases. To effectively reach out to Robert, consider providing insights or exclusive information related to major developments within the pharmaceutical industry such as clinical trial results, FDA decisions, medical device advancements or biotech startup breakthroughs.
As Robert's coverage heavily features private sector announcements and press releases, ensure that any pitch includes newsworthy updates backed by credible sources. Additionally, offering exclusive interviews with key figures in the healthcare and pharmaceutical sector could increase the chances of successful outreach.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Robert Barrie
BiVACOR will now test its total artificial heart in 15 additional patients after completing five successful implants.
By: Robert Barrie
The applications of generative artificial intelligence (GenAI) have reached continuous glucose monitoring after DexCom launched rolled out the technology into its glucose biosensor products.
By: Robert Barrie
Manufacturers of compounded versions of Mounjaro now have a deadline to halt production.
By: Robert Barrie
Manufacturers of compounded versions of Mounjaro now have a deadline to halt production.
By: Robert Barrie
Shares in the company were up 7% at market open following the first approval for a non-invasive spinal cord stimulator for spinal cord injury (SCI) patients.
Sequana expects to launch the device, which is already approved in Europe, in the US in H2 2025.
By: Robert Barrie
Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.
Avita's RECELL platform uses the regenerative properties of the patient's own skin for wound treatment.
By: Robert Barrie
Improper or incomplete reprocessing of the MAJ-891 forceps/irrigation plug has led to reports of patient infections.
By: Robert Barrie
Improper or incomplete reprocessing of the MAJ-891 forceps/irrigation plug has led to reports of patient infections.
(833) 317-6278 
